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Objectives. This study was designed to evaluate the effect of an 
antithrombotic regimen without full early anticoagulation on 
subacute occlusion, bleeding, hospital stay and restenosis after 
elective coronary stenting. 
Background. Snbacute occlusion is a major limitation of stent- 
ing. Aggressive antithrombotic therapy is not fully prophylactic 
against this complication, carries risk of bleeding, prolongs 
hospital stay and reduces cost-effectiveness. 
Methods. We studied 110 consecutive patients (121 lesions) who 
underwent elective Paimaz-Schatz stenting. Intravenous heparin 
was given only during the procedure. After stenting, patients took 
aspirin, dipyridamole, dextran, warfarin and low molecular 
weight heparin (enoxaparin, 40 mg subcutaneously daily, stopped 
when an international normalized ratio of 2 to 3 was achieved). 
The first 52 patients (group A) underwent coronary angiography 
24 h after stenting, and hospital stay was extended until an 
international normalized ratio of 2 to 3.5 was achieved. The 
remaining 58 patients (group B) were discharged 24 h after 
stenting. Clinical and angiographic fullow-up were performed 1 
and 6 months after stenting for all patients. 
Results. In group A the activated partial thromboplastin time 
remained normal (30 -+ 6.2 s [mean -+ SD]) during enoxaparin 
administration, and hospital stay was 9.1 -+ 4.3 days. In group B 
hospital stay was 27 -+ 8 h. No major cardiac events occurred 
within the first month in patients from both groups. At 1 and 30 
days all stented lesions remained patent. Only two patients (1.8%, 
95% confidence interval [CI] 0.32% to 7%) developed bleeding. At 
6 months, the restenosis rate was 22% (95% CI 15% to 30%). 
Conclusions. After coronary stenting with optimal angiographic 
results, this new antithrombotic regimen prevented subacute stent 
occlusion and bleeding, with a brief hospital stay. No detrimental 
effect on the previously reported restenosis rate was observed. 
(J Am Coil Cardiol 1996;27:22-9) 
Coronary stenting is an effective tool in the management of
abrupt or threatened closure after percutaneous transluminal 
coronary angioplasty (1-11). Moreover, the Palmaz-Schatz 
stent is the only mechanical device with proved etficacy to 
prevent coronary restenosis (11-17). However, the risk of 
subacute thrombotic occlusion of stented coronary segments 
remains an unsolved problem (1,3,6,8,10-20). This complica- 
tion occurs in 0.4% to 6% of patients who undergo elective 
stenting, most commonly 3days to 4 weeks after the procedure. 
Subacute stent occlusion frequently results in myocardial in- 
farction during the hospital stay or even after discharge. 
Factors that have been suggested as predictive of thrombotic 
occlusion after coronary stenting can be summarized as fol- 
lows: presence of thrombus in prestentcd coronary lesion, 
persistence of thrombus after stenting, unsatisfactory stenting 
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result or poor distal runoff (3,6,10-13,19-24). Studies in 
animals and humans (12,19,25,26) have suggested the useful- 
ness of intensive antiplatelet and anticoagulant therapy in 
limiting the tendency to stent thrombotic occlusion. Unfortu- 
nately, antiplatelet therapy and optimal anticoagulation by 
intravenous heparin and overlapping warfarin are not fully 
prophylactic against stent hrombosis (5,6,8,19,20). In addition, 
this aggressive antithrombotic regimen requires a long time 
to achieve stable anticoagulation and carries an important 
risk of bleeding complications. Care against hrombotic occlu- 
sion and bleeding complications prolongs the hospital stay 
and impairs the cost-effectiveness ratio of coronary stenting 
(15,16,18,27,28). 
To overcome these problems, investigation is currently 
focusing on obtaining less thrombogenic devices (29), improve- 
ments in stent implantation procedure (high pressure in-stent 
noncompliant balloon dilation and intravascular ultrasound 
monitoring) (30) and optimization of the antithrombotic reg- 
imens (31). 
We formulated the hypothesis that an initial antithrombotic 
therapy without full anticoagulation can improve the incidence 
of bleeding complications and subacute thrombosis n elective 
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coronary stent implantation with optimal angiographic result. 
The immediate, 1- and 6-month clinical and angiographic 
follow-up of elective Palmaz-Schatz coronary stenting with a 
new antithrombotic regimen in 110 consecutive patients and 
the impact of this treatment on hospital stay are described. 
Methods  
Patients. One hundred ten patients were prospectively and 
consecutively enrolled between September 1993 and July 1994 
in an investigational study of elective Palmaz-Schatz coronary 
stenting with a new antithrombotic regimen. The protocol was 
approved by the local ethics committee. All patients provided 
written informed consent. 
There were two groups of patients. Group A included the 
first 52 patients in whom the following protocol was carried 
out: 1) coronary angiography 24 h after stenting; 2) hospital 
stay until a stable international normalized ratio of 2 to 3.5 was 
achieved; and 3) 1- and 6-month clinical and angiographic 
follow-up. Because safety and efficacy of the new antithrom- 
botic regimen were verified in the first group of patients, the 
next 58 patients (group B) underwent the same protocol except 
that 1) coronary angiography 24 h after stenting was not 
performed; and 2) patients were discharged 24 h after stenting 
to elucidate the impact of the new antithrombotic regimen on 
hospital stay. 
Entry criteria included angiographic demonstration of 
single- or multiple-vessel coronary disease with a target lesion 
diameter stenosis >50% as determined by calipers. All pa- 
tients had objective vidence of myocardial ischemia by either 
treadmill exercise or spontaneous ischemia at rest. Advanced 
age, unstable angina, left ventricular dysfunction or congestive 
heart failure, prior myocardial infarction or prior coronary 
revascularization did not preclude participation. Patients with 
contraindications to anticoagulant therapy were excluded. 
Other exclusion criteria were 1) tortuosity of the vessel proxi- 
mal to or in the region of the lesion; 2) diffuse distal disease 
that would compromise outflow from the target lesion; 
3) lesion length >15 ram; and 4) vessel with a reference 
diameter -<3.0 ram. 
Steut implantation procedure. The Palmaz-Schatz coro- 
nary stent was used in all patients. This device is composed of 
two 7-ram long slotted stainless teel tubes connected by a 
l-ram bridging strut (12). The stent was mounted either 
manually on a low profile balloon catheter ("Streak," Ad- 
vanced Cardiovascular Systems, Inc.; or "Speedy," Schneider 
& Co. AG, Buelach, Switzerland) before implantation or 
implanted using a delivery system ("SDS," Johnson & Johnson 
Interventional Systems) according to operator preference. All 
procedures were performed using large-lumen 8F guiding 
catheters and a femoral approach. After an undersized balloon 
dilation for 30 to 60 s, a Palmaz-Schatz stent mounted on a 
balloon ->10% larger with respect o the diameter of adjacent 
nondiseased coronary segment was implanted. After position- 
ing of the balloon with the premounted stent in the stenosis, a 
slow balloon inflation (90 to 120 s) was performed to achieve 
progressive, atraumatic and adequate xpansion of the stent. 
The initial result of stenting was assessed only by angiographic 
criteria. If further expansion was required, a second high 
pressure dilation (14 to 19 arm) was performed by means of a 
noncompliant 0.25- to 0.50-ram oversized balloon ("Pronto," 
USCI-BARD, CR Bard Ireland Limited, Galway, Ireland; or 
"High Energy," Mansfield-Boston Scientific Corporation). 
Initial and follow-up angiography. Predilation and imme- 
diate poststent angiography of the treated stenosis was per- 
formed in at least two orthogonal views best documenting the 
stenosis after intracoronary administration of nitroglycerin. 
Patients from group A underwent a second coronary angio- 
graphic evaluation 24 h after stent implantation, and care was 
taken to replicate the views and nitroglycerin usage of the first 
evaluation. All patients from both groups underwent an angio- 
graphic evaluation under the same conditions 30 days and 6 
months after stent implantation. 
Calculations of percent diameter stenosis, minimal umen 
diameter and reference diameter using an on-line quantitative 
system (HICOR RA43-030.201.03, Siemens) were performed 
before dilation, immediately after stenting and at follow-up 
angiography. This system was also used to measure the diam- 
eter of the balloon during stent expansion. 
Other than measurements done by the operator to guide 
each stenting procedure, all angiographic data were obtained 
by two independent observers. To assess interobserver variabil- 
ity of the HICOR package, 20 routinely acquired digital 
coronary arteriograms were used with a total of 37 stenoses. In 
accordance with the method previously described by Reiber et 
al. (32), interobserver accuracy and precision were, respec- 
tively, 1) 0.02 and 0.21 mm for the reference diameter; 
2) -0.012 and 0.15 mm for the minimal lumen diameter; and 
3) 2.4% and 4.08% for the percent diameter stenosis. 
Medical regimen and clinical follow-up. All patients re- 
ceived aspirin (200 to 500 mg daily) starting at least 72 h 
be-fore angioplasty. During the procedure an intravenous 
heparin bolus of 15,000 IU was given after placement of the 
arterial sheath. Additionally, a dextran-40 intravenous infusion 
(100 ml/h) was given. 
After the procedure, the same medical regimen was used 
in each patient and included 1) aspirin (500 mg daily) indefi- 
nitely; 2) dipyridamole (100 mg orally, three times a day) 
for 3 months; 3) warfarin; 4) intravenous dextran-40 infusion 
(50 ml/h) during the first 24 h; and 5) subcutaneous low 
molecular weight heparin (enoxaparin, 40 mg daily) (Fig. 1). 
Warfarin was started 12 h after the procedure and contin- 
ued for 3 months, tritrated to an international normalized ratio 
of 2.0 to 3.5. 
Subcutaneous low molecular weight heparin administration 
was started 6 h after stent implantation, and no patient 
received intravenous heparin during this period or afterward. 
In every patient subcutaneous low molecular weight heparin 
was continued until an international normalized ratio of 2.0 
was achieved. 
Activated partial thromboplastin time and international 
normalized ratio were determined aily during hospital stay. 
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Figure 1. Schematic representation f antithrombotic 
regimen, d = days; INR = international normalized 
ratio; IV = intravenously; m ~- months; PO = orally; 
PTCA = percutaneous transluminal coronary angio- 
plasty; QD - every day; SC = subcutaneously; TID = 
three times a day. 
Patients from group A were discharged when a stable interna- 
tional normalized ratio of 2 to 3.5 was achieved. Group B 
patients were discharged 24 h after stenting. These patients 
received low molecular weight heparin and warfarin on an 
outpatient basis. A complete clinical evaluation, including 
exercise testing using the Bruce protocol on a computerized 
treadmill system (Case 15, Marquette Electronic Inc.), was 
performed by every patient at the time of coronary angiogra- 
phy, 1 month and 6 months after stent implantation. 
Because 24-b follow-up coronary angiography was part of 
the protocols, the vascular sheath was removed 24 h after stent 
implantation i group A patients. The sheath was removed 6h 
after the procedure in the remaining patients (group B). 
Antithrombotic therapy was neither stopped nor modified 
before or after sheath removal (Fig. 1). 
Definitions. Events that occurred uring the procedure or 
at follow-up were defined as follows: Successful stent deploy- 
ment = complete passage of the stent across the target lesion 
with expansion of the stent o the desired iameter. Immediate 
angiographic success = a residual stenosis <20% after proce- 
dure assessed by on-line angiography. Adequate xpansion of 
the stent = complete and homogeneous balloon inflation 
during stent implantation assessed by on-line angiography in
two orthogonal views with a balloon/vessel ratio >1 and a 
residual stenosis <20%. Stent acute closure = total occlusion of 
the stent within 24 h of delivery. Subacute closure = total stent 
occlusion between 24 h and 4 weeks after delivery. Clinical 
success = immediate angiographic success without major isch- 
emic complication (myocardial infarction, bypass surgery or 
death) or acute or subacute occlusion during the first month. 
Major bleeding complication = any bleeding event resulting in 
transfusion. Major vascular complication = any vascular event 
(e.g., pseudoaneurysm, arteriovenous fistula or hematoma) 
resulting in either transfusion or surgical repair. 
Statistical analysis. At the outset of the study, the size of 
the required sample (100 patients) was based on an assumed 
rate of bleeding complications of 13.5% (16) and a reduction 
of that rate to -<5% without any increase in the subacute stent 
occlusion rate >3.5% (16) (alpha error of 0.05 and a power of 
0.80). To compensate for unsuccessful interventions and losses 
to follow-up, the sample was enlarged by 10% (to 110 pa- 
tients). Continuous variables are presented as mean value + 
SD and were analyzed by a two-tailed t test. When repeated 
measurements of continuous variables were performed, the 
effects of time, groups of patients and the interaction between 
both were analyzed by means of multiple analysis of the 
variance (MANOVA). Categoric variables are expressed as 
percent and were analyzed by the chi-square test or by the 
Fisher exact est when necessary. The 95% confidence intervals 
were calculated. A p value <0.05 was considered statistically 
significant. 
Resu l ts  
Baseline patient and vessel characteristics. Elective place- 
ment of a Palmaz-Schatz coronary stent was attempted in 121 
lesions of 110 patients who had no exclusion criteria and were 
included in the study. Table 1 shows the baseline clinical 
characteristics of our patients. The clinical profiles of the 
patients included in groups A and B were similar (mean [_+SD] 
age 61 _+ 11 years, range 31 to 84). Forty-nine patients (45%) 
were ---65 years old, and there were 92 men (84%). Seventy-six 
patients (69%) had experienced unstable angina before the 
planned procedure, and 7 (6%) had a history of recent 
myocardial infarction (< 1 month) related to the stented artery. 
Multivessel disease was present in 65 patients (59%), and 
mean left ejection fraction was 0.59 _-2- 0.11 (range 0.28 to 0.88). 
Two patients had undergone previous coronary artery bypass 
grafting. One hundred seventeen target lesions (97%) were 
located in native coronary arteries (108 new, 9 restenotic 
lesions), and 4 (3.3%) were located in venous grafts (all new 
lesions). There were no differences in baseline vessel charac- 
teristics between the two groups (33) (Table 2). 
Immediate results. The stent was successfully deployed 
and adequately expanded in 120 (99%) of 121 lesions. One 
patient had two successful stent deployments in two lesions of 
a right coronary artery bypass graft, but the stent delivery, 
system failed to cross another successfully predilated stenosis 
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Table 1. Baseline Clinical Characteristics of the Patients Included in 
the Study* 
Group A Group B All Patients 
(n = 52) (n - 58) (n ~ 110) 
Mean (+_SD) age (yr) 62 + 11 60 _+ 11 61 +_ 11 
Male 43 (83) 49 (84) 92 (84) 
Unstable angina 36 (69) 40 (69) 76 (69) 
Stable angina 16 (31) 18 (31) 34 (31) 
Prior MI 23 (44) 24 (41) 47 (43) 
Prior MI (stented artery) 15 (29) 23 (40) 38 (34) 
Recent (<1 too) 6 (12) 1 (2) 7 (6) 
>1 mo 9 (17) 22 (38) 31 (28) 
Diabetes 4 (8) 8 114) 12 (11) 
Hypertension 22 (42) 21 (36) 43 (39) 
Hyperlipidemia 23 (44) 24 (41) 47 (43) 
Smoking 24 (46) 32 (55) 56 (51) 
1-vessel disease 23 ('44) 22 (38) 45 (41) 
2-vessel disease 19 (37) 20 (35) 40 (36) 
3-vessel disease 10 (19) 16 (27) 25 (231 
*p - NS for between-group differences for all variables analyzed. Unless 
otherwise indicated, data presented are number (%) of patients. MI myocar- 
dial infarction. 
located in the left anterior descending bypass graft and was 
retrieved without any incident. In the remaining 120 lesions, 
immediate angiographic success was achieved using only one 
stent per lesion. Mean final balloon size used to expand the 
stent was 3.8 _+ 0.3 mm, and mean maximal inflation pressure 
achieved was 12.0 + 2.7 atm. Immediate angiographic success 
Table 2. Baseline Angiographic Characteristics* 
Group A Group B All Lesions 
(n = 58) (n -  63) (n 121) 
Reference diameter (ram) 3.3 +_ 0.6 3.3 + 0.6 3.3 + (1.6 
Preangioplasty MLD 1.07 _+ 0.4 1.1 + 0.4 1.08 + 0.4 
Stenosis (%) 68 +_ 11 67 _+ 11 67 + 11 
Artery dilated 
LAD 32 (55) 40 (63) 72 (59) 
LCx 11 1191 9114) 20 117) 
RCA 12 (21) 13 (21) 25 (21) 
SVG 3 (5) 1 (2) 4 (3) 
Target lesion 
New native 52 (90) 56 (89) 108 (89) 
Restenotic native 3 (5) 6 (9.5) 9 (7.4) 
New vein graft 3 (5) 1 11.5) 4 (3.3) 
Restenotic vein graft 0 0 0 
Eccentric 39 (67) 48 (76) 87 (72) 
Multiple irregularities 14 (24) 25 (40) 19 (32) 
Lesion typet 
A 13 (22) 8 (13) 21 (17) 
B, 30 (52) 28 (44) 58 (48) 
B~ 13 (22) 25 (40) 38 (31) 
C 2 (3) 2 (3) 4 (3) 
*p - NS for between-group differences for all variables analyzed, tAmerican 
College of Cardiology/American Heart Association classification (33). Data 
presented are mean value _+ SD or number (%) of lesions. LAD left anterior 
descending coronary, artery; LCx - left circumflex coronary artery; MLD - 
minimal lumen diameter; RCA = right coronary, artery; SVG - saphenous vein 
graft. 
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Figure 2. Angiographic changes inminimal lumen diameter (MLD). 
*p < 0.01 for minimal lumen diameter at 6 months versus before 
angioplasty and at 24 h and 30 days after stenting and for preangio- 
plasty minimal lumen diameter versus 24 h, 30 days and 6 months after 
stenting, tp < 0.05 for minimal lumen diameter at 30 days versus 24 h 
after stenting. 
was achieved in all 120 stents implanted, and successful 
stenting resulted in an increase in mean lumen diameter 
from 1.08 _+ 0.4 to 3.5 +_ 0.5 mm (p < 0.001) (Fig. 2), with a 
residual stenosis of -8  + 17% and an angiographic on-line 
balloon/vessel ratio of 1.17 + 0.2. Adequate xpansion of the 
stent required the use of noncompliant balloons in 41 lesions 
(34%), in which a mean pressure of 15 + 4 atm was achieved. 
Forty-four (40%) of the 110 patients underwent additional 
balloon angioplasty in another lesion not suitable for stenting 
during the same procedure. 
Clinical and angiographic follow-up. All group A patients 
and lesions underwent angiographic evaluation at 24 h after 
stenting (mean 22.3 _+ 1.5 h, range 20 to 28). No elastic recoil 
was observed, and all lesions evaluated remained patent, with 
normal Thrombolysis in Myocardial Infarction (TIMI) grade 3 
flow (34). In-hospital clinical success was achieved in all 
patients of both groups, and no patient developed myocardial 
ischemic events during the hospital stay. Figure 3 shows the 
activated partial thromboplastin time and international nor- 
malized ratio changes during the hospital stay of patients in 
group A. Mean activated partial thromboplastin me 24 h after 
the procedure was 30.1 _+ 6.2 s (control mean value 30 s) 
without significant changes during the first 2 days. Eighty-nine 
percent of group A patients had an international normalized 
ratio >2 on the third day after stenting. Patients in group B 
had a mean activated partial thromboplastin ime and interna- 
tional normalized ratio of 36 _ 7 s and 1.2 +_ 0.3, respectively, 
before discharge, and 69% had an international normalized 
ratio >2 on third day after stenting. Mean hospital stay was 
9.1 _+ 4.3 days in group A, whereas patients in group B were 
discharged 24 h after intervention. 
One-month clinical and angiographic follow-up was ob- 
tained in all patients and lesions from both groups (mean 
31.6 _+ 3.5 days, range 28 to 36). No patient developed acute 
myocardial infarction, needed bypass surgery or died during 
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Figure 3. Changes in international normalized ratio (INR [triangles]) 
and activated partial thromboplastin time (AFIT [squares]) after 
stenting in a patient from group A. 
this period. Although 5% of patients (three from group A, 
three from group B) experienced typical angina, neither occlu- 
sion nor restenosis of the stented coronary segment was 
observed. Patients with complete revascularization did not 
manifest evidence of myocardial ischemia during exercise 
testing, which appeared in 7 (16%) of 45 patients with incom- 
plete revascularization. During the hospital stay and 1 month 
thereafter, only 2 (1.8%) of the 110 patients (95% confidence 
interval [CI] 0.32% to 7%) developed bleeding complications. 
One patient from group B developed a groin hematoma 
requiring transfusion 4 h after intervention. Another patient 
from the same group had gastrointestinal bleeding requiring 
transfusion 20 days after intervention. The remaining 108 
patients from both groups did not develop bleeding or vascular 
complications during 1 month of follow-up. One month after 
intervention, all stented coronary segments remained patent. 
In other words, subacute stent thrombosis was not docu- 
mented. At this time, a slight reduction i  lumen diameter was 
observed (Fig. 2). 
Six-month clinical and angiographic follow-up were ob- 
tained for all patients and lesions (mean 184.8 _+ 6.3 days, 
range 169 to 197) (Fig. 2). As Figure 2 shows, minimal umen 
diameter decreased significantly in both groups in relation to 
its value at 30 days after stenting. According to the ->50% 
stenosis criterion, a restenosis rate of 22% (95% CI 15% to 
30%) of the stented lesions was observed in the overall cohort. 
Major ischemic events (acute myocardial infarction, bypass 
surgery or death) had not appeared at the end of follow-up in 
either group. Angina or myocardial ischemia, or both, at 
exercise test was observed in 25 patients (23%) (11 from group 
A, 14 from group B). It was related to restenosis of a stented 
lesion in 10 patients (9%, 95% CI 5% to 16%) and to previous 
or new significant stenosis in nonstented coronary segments in 
the remaining 15 patients. 
Discuss ion  
The present study shows that a high rate of clinical success 
and a reasonable r stenosis rate can be obtained without acute 
or subacute occlusion after successful elective Palmaz-Schatz 
coronary stenting uided by angiography and followed by a 
new antithrombotic regimen with no effect on activated partial 
thromboplastin time. Moreover, this regimen was associated 
with a very low rate of bleeding, and patients with stenting 
could be discharged 24 h after intervention. 
Stenting in coronary angioplasty. Several studies (1-11) 
have proved the usefulness of stenting in the management of 
abrupt or threatened closure after percutaneous transluminal 
coronary angioplasty. Importantly, Palmaz-Schatz elective cor- 
onary stenting is the only effective mechanical approach for 
prevention of restenosis (11,14-17). In preventing restenosis 
of an already restenotic lesion, Palmaz-Schatz coronary stent- 
ing seems to have a low likelihood of subsequent restenosis 
compared with conventional balloon redilation (11,13,14). 
Data from nonrandomized studies (11,14) using the Palmaz- 
Schatz stent suggested that this device provides a low fre- 
quency of restenosis n new coronary lesions. The recent Stent 
Restenosis Study (STRESS) (15) and Belgium and Nether- 
lands Stent (BENESTENT) (16) randomized clinical trials 
involving almost 1,000 patients concluded that the Palmaz- 
Schatz stent significantly reduces restenosis n focal new native 
coronary lesions compared with balloon angioplasty. Neverthe- 
less, subacute thrombosis may result in total occlusion, myo- 
cardial infarction and death. This complication, which oc- 
curred most commonly 3 days to 3 weeks after implantation i  
0.4% to 6% of cases after elective stenting (11,12,14-16) and 
in >15% after rescue indications (6,8,11), must be considered 
the major limitation of stenting at present (18). Aspirin, 
dipyridamole, dextran, intravenous heparin and warfarin are 
usually administered to prevent subacute stent occlusion. 
Compared with conventional coronary angioplasty, this regi- 
men is associated with a higher frequency of bleeding and 
vascular complications (9.3% for the STRESS trial, 13.5% for 
the BENESTENT trial), which increase morbidity (15,16,18). 
Time to achieve stable anticoagulation a d care to prevent 
stent thrombotic occlusion or bleeding complications extend 
the hospital stay and result in a substantial increase in hospital 
charges compared with that after balloon angioplasty or direc- 
tional atherectomy (11,27,28). 
Thrombotic occlusion after coronary stenting. Like any 
other vascular prosthetic surface, stents are thrombogenic. 
Although the thrombogenicity of a stent depends on hemato- 
logic factors, rheologic factors, such as blood flow patterns and 
shear stress, can also affect the severity and consequences of 
the thrombotic process (35-37). Recent observations (38) 
proved that significant stenosis after angioplasty increases 
shear stress and dramatically increases platelet deposition and 
thrombosis, leading to total thrombotic occlusion. Successful 
coronary stenting totally eliminates tenosis and normalizes 
local flow pattern, which itself could reduce thrombus deposi- 
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tion. In this setting, thrombotic occlusion of the stent seems to 
be unlikely (37,39,40). 
The initial clinical experience with the Wallstent (25) and 
Palmaz-Schatz stent (12) showed a high frequency of subacute 
stent thrombosis, for which aggressive antiplatelet therapy 
(aspirin plus dipyrydamole plus dextran) in combination with 
heparin and warfarin was recommended. Nevertheless, opti- 
mal anticoagulation using this regimen failed to be an inde- 
pendent predictor of stent hrombosis (20). Thus, the absolute 
necessity for full early anticoagulation after coronary stenting 
has been questioned. In fact, some studies (30,41) and our 
preliminary data (42) showed a very low rate of subacute 
occlusion after optimal stent deployment, although patients 
were under minimal or no anticoagulation therapy. The results 
of the present study, in which subacute occlusion was not 
observed, are congruent with these observations and support 
the hypothesis that full early anticoagulation is not necessary 
after elective coronary stenting with optimal angiographic 
result. 
Angiography versus intravascular ultrasound for coronary 
stenting guidance. Recent studies (30,43) have demonstrated 
that when the poststenting result assessed by coronary ultra- 
sound is optimal, the risk of subacute occlusion is very low 
despite the absence of anticoagulation treatment. Moreover, 
intracoronary ultrasound seems to be a useful tool to identify 
a suboptimal result of stenting caused by incomplete or 
asymmetric stent expansion that could be improved with 
further high pressure dilations (30,43,44). In the present study, 
on-line angiographic data were the only criteria used to assess 
the result of stenting and to determine the need of further 
interventions. Although initial stent implantation pressure was 
relatively high (12.0 +_ 2.7 atm), further high pressure dilation 
(15 + 4 atm) by means of a noncompliant balloon was 
considered necessary in 34% of lesions. An optimal result was 
eventually achieved in all cases, with a final minimal lumen 
diameter of 3.5 + 0.5 ram. A good distal runoff of the stented 
artery was always present. Under these conditions, subacute 
occlusion of stent was not observed espite a subtherapeutic 
level of anticoagulation (Fig. 3) between 12 h and 2 days after 
the procedure. Thus, our results coincide with the opinion that 
on-line angiography together with the initial strategy of high 
pressure dilation might be a good alternative to intracoronary 
ultrasound for guidance of stenting and design of poststenting 
treatment (45). 
Bleeding complications, subacute thrombosis and antico- 
agulation therapy after coronary stenting: influence on mor- 
bidity and hospital stay. Bleeding from anticoagulation ther- 
apy is a major limitation of stenting because it is quite frequent 
(13.5% in the BENESTENT trial) (16), causes high morbidity, 
prolongs the hospital stay and worsens cost-effectiveness 
(1,2,5,6,8-16,18,27,28). Thus, the development of new antithrom- 
botic designs more effective against bleeding and subacute occlu- 
sion is a major challenge in coronary stent investigation. 
Low molecular weight heparins are very potent antithrom- 
boric agents with advantages over standard intravenous hepa- 
rins: 1) greater potential antithrombotic effect (not inhibited by 
platelet factor 4 [PF4] released uring coagulation and access 
to factor Xa bound to the platelet membrane, contrary to 
standard heparin); 2) lower bleeding potential because of its 
minimal effect on platelet function and vascular permeability; 
3) lower thrombocytopenia potential; and 4) reliable anticoag- 
ulation and predictable anticoagulant response with a fixed 
dose without a need for monitoring (minimal protein binding 
and excellent bioavailability) (46-50). There is clinical evi- 
dence (50) for the usefulness of this therapy in preventing in 
vivo thrombosis of human blood exposed to artificial surfaces. 
These data suggest an active intervention of this treatment 
against initial stent thrombosis. 
Risk of subacute thrombotic occlusion of stented coronary 
segments exists until endothelization is completed. Several 
studies (11,15,16) have shown a maximal incidence of this 
complication between 3 and 7 days after intervention. Al- 
though in vivo data have not been reported in relation to 
neointimal coverage of Palmaz-Schatz coronary stents in hu- 
mans, recent serial angioscopic observations with the Wiktor 
stent suggest hat complete neointimalization of the stent in 
human coronary arteries is delayed with regard to observations 
in animal models (1 to 3 weeks), and this process probably 
requires a period of nearly 3 months (51). 
In the present study, the antithrombotic treatment was 
designed according to these chronologic, pharmacologic and 
anatomic onsiderations. This treatment caused a very low 
frequency of bleeding, which was probably related to the low 
anticoagulation level achieved uring the 2 days after sheath 
removal. Conversely, subacute stent occlusion was not ob- 
served, which could be related to two factors: 1) the optimal 
angiographic result obtained in all stent implantations, which is 
associated with a favorable rheologic pattern; and 2) the initial 
antiplatelet herapy plus optimal warfarin anticoagulation 
achieved from the third day. The potential role of low molec- 
ular weight heparin in these results requires further study. 
The hospital stay after coronary stenting is significantly 
longer than that after balloon angioplasty (8.5 vs. 3.1 days in 
the BENESTENT study [16], 5.8 vs. 2.8 days in the STRESS 
study [15]). In the second phase of the present study, patients 
were discharged 24 h after stenting, and no complications 
occurred uring the first 15 days. This finding confirms that the 
antithrombotic regimen used may overcome the limiting effect 
of stenting on hospital stay. 
Restenosis. The angiographic restenosis rate reported in 
the present study did not differ from that observed after 
elective coronary stenting in several studies (14-16). This 
finding suggests the absence of a detrimental effect of this 
antithrombotic regimen in the poststent restenotic process. 
Study limitations and conclusions. Our cohort was not 
compared with a control group either without initial anticoag- 
ulation or with classical initial full anticoagulation. Therefore, 
definitive clinical implications of the present study, and the 
impact of its results on the hospital stay and cost-effectiveness 
of coronary stenting, require further investigation. Neverthe- 
less, the results are relevant because they support he hypoth- 
esis that after optimal coronary stent deployment guided by 
28 FERNANDEZ-AVILI~'S ET AL. JACC Vol. 27, No. 1 
STENTING AND ANTITHROMBOTIC THERAPY January 1996:22-9 
angiography only, the initial combination of low molecular 
weight heparin plus antiplatelet therapy followed by delayed 
anticoagulation with warfarin prevents subacute stent throm- 
botic occlusion and bleeding complications, with a very brief 
hospital stay. Also, this regimen seems to have no detrimental 
effect on the previously reported restenosis rate. 
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